BLRX - BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

AI Brief Summary from the article:

BLRX just showed GLIX1 plus olaparib at low doses matched cisplatin in a real patient derived ovarian cancer model. Not cell lines. Actual human tumor tissue.

AstraZeneca sells five billion dollars a year of olaparib. It only works in half of ovarian cancer patients. GLIX1 appears to unlock it for the other half.